Swiss Life AM entity launches tender bid targeting Everfuel
Sep 03, 2024 10:16 CESTDanish biotech firm Novozymes A/S (CPH:NZYM-B) expects 2016 to be a challenging year for sales growth as low oil prices take a toll on its bioenergy business.
Bioenergy sales contracted 5% organically compared to 2014, the company's 2015 report showed this week. In the fourth quarter, they registering an even steeper 15% year-on-year drop.
The strong performance in the agriculture and feed segment compensated for the weakness in bioenergy so Novozymes reported organic sales growth of 4% for 2015. The firm expects its sales to the bioenergy industry to be also down in 2016, while it guided for 3%-5% organic growth in 2016 overall sales.
"Novozymes maintains its ambition to accelerate sales growth to 8-10% organically. However, as a result of the current depressed commodity prices and the uncertainties these entail for Bioenergy and growth in emerging markets, Novozymes expects annual organic sales growth from 2017 through to the end of the decade to be in line with the historical performance of 6-7%."
The bioenergy business, which offers enzymes for biofuel production including starch-based and cellulosic ethanol, is suffering as low oil and ethanol prices reduce profitability for customers and fuel uncertainty as to when second-generation biofuels will commercialise.
Swiss Life AM entity launches tender bid targeting Everfuel
Sep 03, 2024 10:16 CESTBetter Energy to delay 3 GW of Danish PV projects amid negative prices
Sep 19, 2024 11:14 CESTEurowind, Wind Estate set up EUR-400m wind JV in Denmark
Sep 18, 2024 11:01 CESTVattenfall inaugurates 344-MW Vesterhav Nord and Syd in Danish waters
Sep 12, 2024 15:26 CESTNordic Solar enters BESS market with 10-MWh project in Denmark
Sep 11, 2024 15:12 CESTH2 Energy seeks to link 1-GW Danish hydrogen plant to German network
Sep 10, 2024 11:55 CEST